Sun Builds On Tildrakizumab Hopes With Almirall Pact
Sun Pharma has struck a licensing deal with Almirall for its late-stage psoriasis asset tildrakizumab, building on its recent clinical advancement and raising hopes of significant upsides for the Indian firm. The IL-23p19 inhibitor also adds to Almirall's broad derma portfolio amid the Spanish firm's acquisitive interest in the space.
You may also be interested in...
Ichnos Gets Going With Almirall Deal, Multiple Myeloma Bispecifics Add Sheen
Glenmark’s US-based innovation arm Ichnos delivers first licensing deal for IL-1RAP antagonist, while early data for a bispecific antibody demonstates promising activity in multiple in vitro and in vivo tumor models relative to daratumumab and magrolimab.
Sun Builds On Psoriasis Data But Can It Hold In Crowded Space?
Sun Pharma’s executive vice president, biologics and dermatology, Jesper Ostergaard Jensen, elaborates on some aspects of the recent encouraging data around the company’s late stage psoriasis asset, tildrakizumab. Jensen also tells Scrip that the firm is upbeat about its acne and photodynamic therapy products in the US.
Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market
India's Sun Pharma, the world's fifth largest specialty generic company, emphasized the "very competitive profile" of its late-stage psoriasis asset, tildrakizumab, at its Q2 earnings, but will that hold in a market that is expected to become increasingly saturated?